An interventional study of blood sampling and Survey using a questionnaire. in Screening for Colon Cancer, Blood Samples and Survey and Questionnaire, sponsored by ADVANCED MARKER DISCOVERY S.L.. Recruiting at 2 sites in 2 countries. Open to participants aged 50 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-27.
Sponsored by ADVANCED MARKER DISCOVERY S.L. · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Colonic Neoplasms with a site in Portugal — 2 open to participants now, 3 under way, 2 of them phase 3. Colonic Neoplasms · Portugal.
Among the 18 studies in Colonic Neoplasms with a site in Portugal, this one has the largest planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2025, is one of 4 with no phase, and was the 18th registered.
2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.
Browse Colonic Neoplasms studies →2 of the 18 studies in Colonic Neoplasms with a site in Portugal are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Portugal, United States, Argentina and 25 more countries
Ages 18+
A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →
Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years to 69 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4,538 is above the median of 75 across 1,711 interventional studies indexed under Colonic Neoplasms.
Median enrollment 874 across the 12 interventional studies, 613 across the 3 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 18 have an industry lead sponsor. The 10 most frequent:
ADVANCED MARKER DISCOVERY S.L. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
ADVANCED MARKER DISCOVERY S.L. has 1 study filed under Colonic Neoplasms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Colonic Neoplasms with a site in Portugal, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this low-risk interventional study is to evaluate whether the PreveCol® test has sufficient efficiency to be considered as a second-line method for the detection of both colorectal cancer and advanced adenomas when used prospectively in the screening population with a previous positive FOBT result, which could include any of the following: both sexes, age 50-69 years, asympthomatic volunteers. The main aims to be answered are:
Participants will provide a blood sample prior to a screening colonoscopy, and complete two questionnaires. They will give their sample, information and clinical data to the investigator or health care personnel.
2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.
This study's planned enrollment of 4,538 is above the median of 75 across 1,711 interventional studies indexed under Colonic Neoplasms.
Browse Colonic Neoplasms studies →ADVANCED MARKER DISCOVERY S.L. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Compared within Colonic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Colorectal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Average-risk participants from the colorectal cancer screening programme with FOBT positive result who are eligible to undergo colonoscopy
Diagnostic Test: blood sampling · Other: Survey using a questionnaire.
PreveCol test based on blood sampling
Also known as: PreveCol
Preference questionnaire for colorectal cancer screening methods
PREMs for colorectal cancer screening programme
Diagnostic value
Value of efficiency through the clinical performance (sensitivity, specificity, positive predictive value and negative predictive value) of PreveCol® after FOBT positive result for detecting neoplastic lesions.
Time frame: 12 months
Diagnostic performance of cancer
Value of PreveCol's efficiency in second line for detecting cancer
Time frame: 12 months
Diagnostic performance of lesions
Value of PreveCol's efficiency in second line for advanced lesions
Time frame: 12 months
Value of questionnaires into screening programme
The percentage of number of answers from each preference questions and PREMs
Time frame: 12 months
Safety
Measure the percentage of adverse events and complications directly/indirectly related to interventions of study.
Time frame: 12 months
Plan to share: No
Started Jan 2025 (actual). Primary completion is estimated for Nov 2025, 10 months after the start.
Of 404 interventional studies with no phase under Colonic Neoplasms, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 51. This study's planned 10 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ADVANCED MARKER DISCOVERY S.L.